Pricing

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Generics trigger wallet shock

Prices for some generics are rising, thanks to limited competition.

Experiment cuts cancer costs, ups drug spend

UnitedHealthcare finds drug costs more than doubled.

France ponders off-label Avastin

French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.

Italy: Use Avastin off-label

The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.

Oregon seeks HCV Rx waiver

The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.

China lifts some pricing restrictions

Drug quality problems and shortages are behind the shift that will affect antibiotics, painkillers and vitamins.

Survey finds pharma and payers not aligned

Survey finds pharma and payers not aligned

By

An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.

Sovaldi Rx are being filled, despite payer angst

Sovaldi Rx are being filled, despite payer angst

By

Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

By

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

By

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Insurers struggle with Sovaldi angst

A report indicates that Sovaldi's high price may hurt health-insurance investors.

ASCO will grade drugs

The professional association says it's necessary, because high prices do not indicate impact.

NICE says no to Xofigo, Zaltrap

NICE says no to Xofigo, Zaltrap

By

The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.

Sovaldi price worries states

Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.

NICE wants more Soliris information

The UK watchdog wants to know what's behind the rare-disease drug's high price.

Industry wary of new German pricing rule

Germany's price transparency requirement has the industry worried other markets will demand lower prices.

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

By

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

Few employers contain specialty Rx costs: study

Few employers contain specialty Rx costs: study

By

The third Pharmacy Benefit Management Institute specialty medication survey expects specialty medications, which average around $3,000 per month per patient, will account for 50% of the drug spend within four or five years.

Gilead ponders Sovaldi price break

The drug maker is reportedly talking low rates for India's market.

What payer concerns? Sovaldi ahead of curve

What payer concerns? Sovaldi ahead of curve

By

If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.

NICE gives Aubagio the nod

The price watchdog said Sanofi's oral MS drug Aubagio is a go. The decision follows a September directive to prove the drug's cost-effectiveness.

Patent cliff a drag on 2012 health spend

Patent cliff a drag on 2012 health spend

By

Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.

Antidepressants may have to fight for Part D coverage

CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

BMS pulls new diabetes med in Germany

The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.

Think tank says raise Rx prices for NHS

The National Health Service is expected to have a $49-billion deficit by 2020.

CVS says specialty drug spend to quadruple

CVS says specialty drug spend to quadruple

By

The PBM encourages step-therapy to control costs.

IMS predicts $1T global drug market by 2017

IMS predicts $1T global drug market by 2017

By

The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.

Email Newsletters